Erasca reports FY2023 net loss $125M, cash $322M; clinical updates for naporafenib and ERAS-801

Erasca, Inc.

Net loss $125M ($0.83/share) for FY2023 vs $242.8M ($1.99/share) in prior year; R&D expenses $103.8M.
Cash, equivalents, marketable securities $322M as of Dec 31, 2023, down from $435.6M.
Gained FDA Fast Track Designation for naporafenib + trametinib in NRASm melanoma; planned Phase 3 SEACRAFT-2 initiation H1 2024.
Entered clinical trial collaboration with Novartis for trametinib supply for naporafenib trials at no cost.
Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), ERAS-801 (THUNDERBBOLT-1).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Erasca, Inc. reported financial results for the fiscal quarter and full year ended December 31, 2023.

Period: the fiscal quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 27, 2024, Erasca, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Erasca, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-037161

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.